The development of diabetes mellitus in patients receiving targeted therapies for non-small cell lung cancer (NSCLC) presents a growing clinical challenge. We're accustomed to thinking of type 1 diabetes as an autoimmune condition, characterized by the presence of autoantibodies. But what happens when a patient on lorlatinib, a third-generation ALK inhibitor, develops diabetic ketoacidosis (DKA) and those autoantibodies are nowhere to be found? This case highlights a diagnostic conundrum and forces us to broaden our differential for new-onset diabetes.
The case, recently published, details a patient with ALK-positive NSCLC who, after starting lorlatinib, presented with DKA but lacked the typical autoantibodies associated with type 1 diabetes. This isn't just an academic curiosity. It directly impacts how we approach diagnosis and management in these patients. Are we missing a subtype of drug-induced diabetes? And how should we adjust our monitoring strategies to catch this complication early?
Clinical Key Takeaways
lightbulb
- The PivotLorlatinib can induce diabetes even in the absence of autoantibodies, challenging traditional diagnostic paradigms.
- The DataA case report illustrates a patient developing DKA with undetectable GAD65, IA-2, and ZnT8 antibodies after lorlatinib initiation.
- The ActionIncrease vigilance for hyperglycemia in patients on lorlatinib, regardless of pre-existing diabetes risk factors or autoantibody status.
Background: Lorlatinib and Insulin Resistance
Lorlatinib is a third-generation ALK inhibitor used to treat ALK-positive NSCLC. While it has shown remarkable efficacy in overcoming resistance to earlier-generation ALK inhibitors, it comes with a spectrum of adverse effects. Hyperglycemia is among these, but the mechanism remains unclear. Is it a direct effect on pancreatic beta cells, increased insulin resistance, or a combination? The prevailing hypothesis leans towards increased insulin resistance, potentially mediated through effects on lipid metabolism. However, this case challenges the notion that all lorlatinib-induced diabetes is simply a matter of insulin resistance.
Existing guidelines, such as the NCCN guidelines for NSCLC, acknowledge hyperglycemia as a potential side effect of ALK inhibitors and recommend monitoring blood glucose levels. However, they do not specifically address the possibility of autoantibody-negative diabetes or provide guidance on how to differentiate it from other forms of drug-induced hyperglycemia. This case highlights a gap in current recommendations.
Case Presentation: A Diagnostic Puzzle
A patient with ALK-positive NSCLC, treated with lorlatinib, presented with classic symptoms of hyperglycemia - polydipsia, polyuria, and fatigue. Initial lab work confirmed significantly elevated glucose levels and the presence of ketones, indicating DKA. What made this case unusual was the absence of detectable GAD65, IA-2, and ZnT8 autoantibodies. These are the typical markers we associate with type 1 diabetes. The patient had no prior history of diabetes and no family history of autoimmune disease. So, what's going on?
Differential Diagnosis: Beyond Autoimmunity
The absence of autoantibodies narrows the differential diagnosis, but doesn't eliminate diabetes. We must consider other possibilities, including type 2 diabetes exacerbated by lorlatinib, pancreatic damage leading to insulin deficiency, or a unique form of drug-induced diabetes that doesn't trigger an autoimmune response. The authors reasonably excluded typical type 1 diabetes. They also considered the possibility of atypical forms of autoimmune diabetes, such as latent autoimmune diabetes in adults (LADA), but the acute presentation with DKA made this less likely. Drug-induced diabetes, therefore, became the most probable explanation. Lorlatinib’s impact on insulin sensitivity and glucose metabolism clearly played a central role.
Treatment and Outcome: Insulin and Lorlatinib
The patient was initially treated with intravenous insulin to resolve the DKA. Once stabilized, they were transitioned to subcutaneous insulin injections. Here's the critical question: What about the lorlatinib? The decision was made to continue lorlatinib, given its importance in controlling the patient's NSCLC. However, the insulin dose had to be carefully adjusted to maintain glycemic control. This highlights the difficult balancing act clinicians face when managing these patients. Do we prioritize cancer control or minimize the risk of metabolic complications?
Study Limitations: N of 1
Let's be clear: This is a single case report. We can't draw broad conclusions or change clinical practice based on one patient. We have no control group and no way to assess the true incidence of autoantibody-negative diabetes in patients treated with lorlatinib. Furthermore, the underlying mechanism remains speculative. Is lorlatinib directly toxic to beta cells in certain individuals? Does it trigger a non-autoimmune inflammatory response in the pancreas? These are questions that require further investigation. Additionally, the cost-effectiveness of routine autoantibody screening in all patients on lorlatinib is questionable, given the rarity of this presentation.
Clinical Implications: Cost and Monitoring
This case underscores the importance of careful glucose monitoring in patients receiving lorlatinib. Standard screening protocols may not be sufficient to detect this unusual presentation of drug-induced diabetes. Clinicians should consider measuring autoantibodies in patients who develop hyperglycemia while on lorlatinib, particularly if they have no prior history of diabetes or risk factors for type 2 diabetes. This adds to the cost of care. Autoantibody testing can be expensive, and it may not be covered by all insurance plans. Hospitals and clinics need to develop protocols for managing these patients, including algorithms for insulin initiation and dose adjustment. Furthermore, this raises the issue of financial toxicity. Patients may face significant out-of-pocket expenses for insulin, blood glucose monitoring supplies, and specialist visits.
LSF-6813115269 | December 2025
How to cite this article
O'Malley L. Lorlatinib and the enigma of autoantibody-negative diabetes. The Life Science Feed. Published March 7, 2026. Updated March 7, 2026. Accessed March 8, 2026. https://thelifesciencefeed.com/oncology/diabetes/case/lorlatinib-and-the-enigma-of-autoantibody-negative-diabetes.
Copyright and license
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Fact-Checking & AI Transparency
This content was produced with the assistance of AI technology and has been rigorously reviewed and verified by our human editorial team to ensure accuracy and clinical relevance.
References
- Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 87(1), 4-14.
- American Diabetes Association. (2023). Standards of medical care in diabetes. American Diabetes Association.
- Pasi N, Ganda K, Joshi A, et al. New-Onset Autoantibody-Negative Diabetes With DKA Following Lorlatinib Therapy for ALK-Positive NSCLC. JTO Clinical and Research Reports. 2024;5(5):100770.
